James R. Kasinger insider trades

Open-market stock purchases and sales by James R. Kasinger, General Counsel and Secretary at CRISPR Therapeutics AG, from SEC Form 4 filings since May 31, 2017.

Recent trades

DateStockTradeValue
May 29, 2026CRSP CRISPR Therapeutics AGBought (not open market)—
Mar 23, 2026CRSP CRISPR Therapeutics AGSold$149K
Mar 20, 2026CRSP CRISPR Therapeutics AGBought (not open market)—
Mar 20, 2026CRSP CRISPR Therapeutics AGBought (not open market)—
Mar 20, 2026CRSP CRISPR Therapeutics AGBought (not open market)—
Mar 16, 2026CRSP CRISPR Therapeutics AGSold$166K
Mar 14, 2026CRSP CRISPR Therapeutics AGBought (not open market)—
Mar 11, 2026CRSP CRISPR Therapeutics AGSold$148K
Mar 10, 2026CRSP CRISPR Therapeutics AGBought (not open market)—
Feb 19, 2026CRSP CRISPR Therapeutics AGSold$111K
Feb 18, 2026CRSP CRISPR Therapeutics AGBought (not open market)—
Oct 14, 2025CRSP CRISPR Therapeutics AGSold$71.7K
Oct 13, 2025CRSP CRISPR Therapeutics AGBought (not open market)—
Oct 3, 2025CRSP CRISPR Therapeutics AGBought (not open market)—

Companies traded

  • CRSP CRISPR Therapeutics AG: 19 sales, last May 29, 2026

Get free alerts when James R. Kasinger files a new trade →